2026 Global: Blood Product-Competitive Review (2032) report
Description
The 2026 Global: Blood Product-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Grifols S.A., headquartered in Barcelona, Spain, is a leading global producer of plasma-derived medicines and diagnostic products, with a vertically integrated workflow spanning donor recruitment, plasma collection, fractionation, purification, and worldwide distribution. CSL Behring, the plasma-derived therapies division of CSL Limited, is headquartered in Melbourne, Australia, and maintains a broad manufacturing network and commercial footprint across the Americas, Europe, and Asia. Octapharma AG, headquartered in Lachen, Switzerland, operates across immunoglobulins, coagulation factors, and albumin, applying recombinant and human plasma technologies to treat bleeding disorders, immune deficiencies, and critical care conditions. Kedrion Biopharma, the U.S. affiliate of Kedrion S.p.A., is headquartered in Castelnuovo di Porto, Italy, and coordinates production and regulatory affairs to supply plasma-derived therapies to patients worldwide. LFB Group, headquartered in Les Ulis, France, specializes in plasma-derived medicines for rare diseases and maintains a significant European manufacturing footprint alongside international distribution. Together they shape global plasma supply chains today.
Biotest AG, headquartered in Dreieich, Germany, specializes in plasma proteins and therapies for hematology and immunology, maintaining multiple production sites and a global distribution network. Sanquin Plasma Products, based in Amsterdam, Netherlands, operates the national blood bank and exports plasma derivatives, contributing significantly to international supply through collaboration and contract manufacturing. GC Biopharma (Green Cross), headquartered in Seoul, South Korea, represents a major regional supplier of plasma-derived products and invests in research partnerships to expand therapy options. Bio Products Laboratory (BPL), headquartered in Elstree, United Kingdom, has a long history in plasma fractionation and contract manufacturing, supporting hospitals and pharmaceutical partners with high-quality plasma proteins. These institutions collaborate with universities and public health bodies to ensure supply during shortages and crises, emphasizing safety, traceability, and innovation. Their combined capabilities in collection, testing, manufacturing, and distribution underpin patient access to life-saving therapies worldwide. This ecosystem supports resilience across markets globally today.
Fresenius Kabi, headquartered in Bad Homburg vor der Höhe, Germany, is a major global supplier of plasma-derived medicines, intravenous immunoglobulin, albumin, and related infusion therapies, serving hospitals and patients across continents through a broad manufacturing and distribution network. The company leverages centralized manufacturing, rigorous quality systems, and a global logistics framework to ensure access to lifesaving products in routine settings and during emergencies. As a diversified health care company, Fresenius Kabi sustains collaborations with academic centers and clinical researchers to optimize product development, pricing, and patient outcomes, complementing the capabilities of the other players described above and contributing to resilience in the plasma supply chain. As the plasma ecosystem evolves, this portfolio of producers, fractionators, and service providers must maintain stringent safety standards, transparent pricing, and adaptable manufacturing capacity to meet rising demand and public health challenges. Continued collaboration among regulators, industry, and clinicians will propel patient-centered outcomes worldwide today.
Grifols S.A., headquartered in Barcelona, Spain, is a leading global producer of plasma-derived medicines and diagnostic products, with a vertically integrated workflow spanning donor recruitment, plasma collection, fractionation, purification, and worldwide distribution. CSL Behring, the plasma-derived therapies division of CSL Limited, is headquartered in Melbourne, Australia, and maintains a broad manufacturing network and commercial footprint across the Americas, Europe, and Asia. Octapharma AG, headquartered in Lachen, Switzerland, operates across immunoglobulins, coagulation factors, and albumin, applying recombinant and human plasma technologies to treat bleeding disorders, immune deficiencies, and critical care conditions. Kedrion Biopharma, the U.S. affiliate of Kedrion S.p.A., is headquartered in Castelnuovo di Porto, Italy, and coordinates production and regulatory affairs to supply plasma-derived therapies to patients worldwide. LFB Group, headquartered in Les Ulis, France, specializes in plasma-derived medicines for rare diseases and maintains a significant European manufacturing footprint alongside international distribution. Together they shape global plasma supply chains today.
Biotest AG, headquartered in Dreieich, Germany, specializes in plasma proteins and therapies for hematology and immunology, maintaining multiple production sites and a global distribution network. Sanquin Plasma Products, based in Amsterdam, Netherlands, operates the national blood bank and exports plasma derivatives, contributing significantly to international supply through collaboration and contract manufacturing. GC Biopharma (Green Cross), headquartered in Seoul, South Korea, represents a major regional supplier of plasma-derived products and invests in research partnerships to expand therapy options. Bio Products Laboratory (BPL), headquartered in Elstree, United Kingdom, has a long history in plasma fractionation and contract manufacturing, supporting hospitals and pharmaceutical partners with high-quality plasma proteins. These institutions collaborate with universities and public health bodies to ensure supply during shortages and crises, emphasizing safety, traceability, and innovation. Their combined capabilities in collection, testing, manufacturing, and distribution underpin patient access to life-saving therapies worldwide. This ecosystem supports resilience across markets globally today.
Fresenius Kabi, headquartered in Bad Homburg vor der Höhe, Germany, is a major global supplier of plasma-derived medicines, intravenous immunoglobulin, albumin, and related infusion therapies, serving hospitals and patients across continents through a broad manufacturing and distribution network. The company leverages centralized manufacturing, rigorous quality systems, and a global logistics framework to ensure access to lifesaving products in routine settings and during emergencies. As a diversified health care company, Fresenius Kabi sustains collaborations with academic centers and clinical researchers to optimize product development, pricing, and patient outcomes, complementing the capabilities of the other players described above and contributing to resilience in the plasma supply chain. As the plasma ecosystem evolves, this portfolio of producers, fractionators, and service providers must maintain stringent safety standards, transparent pricing, and adaptable manufacturing capacity to meet rising demand and public health challenges. Continued collaboration among regulators, industry, and clinicians will propel patient-centered outcomes worldwide today.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
